ConductScience.org, home

Paper34812432

SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence.

Vargas-Herrera N and 5 others. Lancet Reg Health Am, 2022. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence. Papers, record 34812432. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34812432

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence.
PubMed
Journal
Lancet Reg Health Am
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2022-02-18
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vargas-Herrera NNatalia
2Araujo-Castillo RVRoger V
3Mestanza OOrson
4Galarza MMarco
5Rojas-Serrano NNancy
6Solari-Zerpa LLely

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References8

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134075212SARS-CoV-2 variants, spike mutations and immune escape.Nat Rev Microbiol2021https://conductscience.org/library/papers/34075212PubMed
234022148Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.Lancet Glob Health2021https://conductscience.org/library/papers/34022148PubMed
333853970Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.Science2021https://conductscience.org/library/papers/33853970PubMed
433909850SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil.Rev Inst Med Trop Sao Paulo2021https://conductscience.org/library/papers/33909850PubMed
534370324Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern.J Med Virol2021https://conductscience.org/library/papers/34370324PubMed
633789086The variant gambit: COVID-19's next move.Cell Host Microbe2021https://conductscience.org/library/papers/33789086PubMed
734968415The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.Cell Rep2022https://conductscience.org/library/papers/34968415PubMed
833404586Genetic Variants of SARS-CoV-2-What Do They Mean?JAMA2021https://conductscience.org/library/papers/33404586PubMed

Download CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42424291Implementation of a SARS-CoV-2 genomic surveillance network as a strategy to face other health challenges in Peru.Rev Peru Med Exp Salud Publica2026https://conductscience.org/library/papers/42424291PubMed
41513994Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024.Commun Med (Lond)2026https://conductscience.org/library/papers/41513994PubMed
41018758Genomic surveillance of SARS-CoV-2 in the Andean Community (2020-2024): integrating regional sequencing efforts from Colombia, Ecuador, Peru, and Bolivia through "ORAS-CONHU" program.Front Public Health2025https://conductscience.org/library/papers/41018758PubMed
40333293Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines (Basel)2025https://conductscience.org/library/papers/40333293PubMed
39166636Detection of SARS-CoV-2 variants in hospital wastewater in Peru, 2022.Rev Peru Med Exp Salud Publica2024https://conductscience.org/library/papers/39166636PubMed
38987406Early mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants in Chile.Sci Rep2024https://conductscience.org/library/papers/38987406PubMed
38907313Dispersion of SARS-CoV-2 lineage BA.5.1.25 and its descendants in Peru during two COVID-19 waves in 2022.Genomics Inform2024https://conductscience.org/library/papers/38907313PubMed
38900824The role of socio-economic disparities in the relative success and persistence of SARS-CoV-2 variants in New York City in early 2021.PLoS Pathog2024https://conductscience.org/library/papers/38900824PubMed
38473117Possible Spreading of SARS-CoV-2 from Humans to Captive Non-Human Primates in the Peruvian Amazon.Animals (Basel)2024https://conductscience.org/library/papers/38473117PubMed
38393135Genomic and Phylogenetic Characterisation of SARS-CoV-2 Genomes Isolated in Patients from Lambayeque Region, Peru.Trop Med Infect Dis2024https://conductscience.org/library/papers/38393135PubMed
38170049Predicting the spread of SARS-CoV-2 variants: An artificial intelligence enabled early detection.PNAS Nexus2024https://conductscience.org/library/papers/38170049PubMed
38045771Regional clustering and waves patterns due to COVID-19 by the index virus and the lambda/gamma, and delta/omicron SARS-CoV-2 variants in Peru.Gates Open Res2022https://conductscience.org/library/papers/38045771PubMed
37524331Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru.Am J Trop Med Hyg2023https://conductscience.org/library/papers/37524331PubMed
37376681The Lambda Variant in Argentina: Analyzing the Evolution and Spread of SARS-CoV-2 Lineage C.37.Viruses2023https://conductscience.org/library/papers/37376681PubMed
37322028Phylodynamic of SARS-CoV-2 during the second wave of COVID-19 in Peru.Nat Commun2023https://conductscience.org/library/papers/37322028PubMed
36935725Overview of the SARS-CoV-2 genotypes circulating in Latin America during 2021.Front Public Health2023https://conductscience.org/library/papers/36935725PubMed
36851324
Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.
Vaccines (Basel)2023https://conductscience.org/library/papers/36851324PubMed
36848558Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities.Proc Natl Acad Sci U S A2023https://conductscience.org/library/papers/36848558PubMed
36786950Evidence of natural selection and dominance of SARS-CoV-2 variant Lambda (C.37) over variants of concern in Cusco, Peru.Arch Virol2023https://conductscience.org/library/papers/36786950PubMed
36438034SARS-CoV-2 variants: Impact on biological and clinical outcome.Front Med (Lausanne)2022https://conductscience.org/library/papers/36438034PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34812432

GET https://conductscience.org/api/papers/v1/34812432/cited_by?page=2